In just two neutron experiments, scientists discovered remarkable details about the function of an enzyme that can aid drug design for aggressive cancers.
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond
MADRID — Patients with previously treated small-cell lung cancer (SCLC) obtained durable responses with either of two doses of the bispecific T cell-engaging (BiTE) antibody